232 recruiting. 232 Phase 2, 75 Phase 1, 10 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 232 | Recruiting 232 |
| Phase 1 | 75 | Recruiting 75 |
| Phase 3 | 10 | Recruiting 10 |
Follow Leukemia, Lymphoid: new trials by email Literature Review of Leukemia, Lymphoid trials Research Report on Leukemia, Lymphoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Nemtabrutinib, Lisocabtagene Maraleucel - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2026-12-01 | 2026-10-29 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Jennifer Woyach | 25 | 2026-11-01 | 2026-10-15 |
| Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Kerry Rogers | 155 | 2026-10-01 | 2026-08-31 |
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NX-5948, venetoclax, rituximab - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 150 | 2026-09-30 | 2026-10-22 |
| A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) BGB-16673, BGB-11417 - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2026-08-20 | 2026-10-29 |
| A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies Lacutoclax+Rocbrutinib - Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 92 | 2026-07-14 | 2026-07-30 |
| A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL Lacutoclax - Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 75 | 2026-07-14 | 2026-07-30 |
| Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Jennifer Woyach | 50 | 2026-07-13 | 2026-09-28 |
| Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD Mosunetuzumab - Lymphocytic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-07-09 | 2026-08-12 |
| Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-07-05 | 2026-10-15 |
| CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine - Acute Lymphoblastic Leukemia, B-All | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-06-16 | 2026-10-26 |
| MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab Acalabrutinib, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Recruiting | AstraZeneca | 80 | 2026-06-04 | 2026-10-23 |
| A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients Zanubrutinib and sonrotoclax - CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 24 | 2026-06-01 | 2026-06-26 |
| Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-05-27 | 2026-10-06 |
| Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection Combination of Dolutegravir + Tenofovir DF for treatment of HTLV-1 infection, Dolutegravir (DTG) - HTLV-1 Infection, HTLV I Associated Myelopathies | Phase 2 | Recruiting | Carlos Brites | 146 | 2026-05-07 | 2026-06-02 |
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia Ruxolitinib, Cladribine, Venetoclax - T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 36 | 2026-04-28 | 2026-08-12 |
| Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity Tirzepatide, Resistance Exercise, Lifestyle Counseling - Acute Lymphoblastic Leukemia, Obesity | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 20 | 2026-04-23 | 2026-06-04 |
| A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies Emavusertib, Zanubrutinib - Chronic Lymphocytic Leukemia, B-cell Malignancies | Phase 2 | Recruiting | Curis, Inc. | 108 | 2026-04-23 | 2026-06-12 |
Showing 20 of 232. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (112) · Leukemia, Lymphocytic, Chronic, B-Cell (75) · Leukemia, Myeloid, Acute (44) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (31) · Leukemia, Biphenotypic, Acute (30) · Myelodysplastic Syndromes (30) · Lymphoma, Non-Hodgkin (29) · Leukemia (25) · Recurrence (19) · Burkitt Lymphoma (18) · Lymphoma (18) · Lymphoma, Mantle-Cell (16) · Lymphoma, Follicular (15) · Lymphoma, Large B-Cell, Diffuse (13) · Hematologic Neoplasms (12)
Hemic and Lymphatic Diseases (232) · Lymphatic Diseases (232) · Hematologic Diseases (231) · Immune System Diseases (231) · Immunoproliferative Disorders (231) · Lymphoproliferative Disorders (231) · Neoplasms by Histologic Type (231) · Neoplasms (227) · Leukemia (207) · Pathological Conditions, Signs and Symptoms (117) · Pathologic Processes (113) · Disease Attributes (107) · Chronic Disease (92) · Leukemia, B-Cell (70)
Cyclophosphamide (49) · venetoclax (41) · Cytarabine (25) · Dexamethasone (25) · Methotrexate (24) · fludarabine (22) · Vincristine (21) · blinatumomab (20) · Specimen Handling (19) · Biopsy (17) · obinutuzumab (14) · Rituximab (13) · Mercaptopurine (12) · Prednisone (12) · Whole-Body Irradiation (12)
M.D. Anderson Cancer Center (16) · Institute of Hematology & Blood Diseases Hospital, China (11) · Fred Hutchinson Cancer Center (10) · AstraZeneca (5) · City of Hope Medical Center (5) · National Cancer Institute (NCI) (5) · St. Jude Children's Research Hospital (5) · First Affiliated Hospital of Zhejiang University (4) · Masonic Cancer Center, University of Minnesota (4) · Memorial Sloan Kettering Cancer Center (4) · The First Affiliated Hospital of Soochow University (4) · The First Affiliated Hospital of Zhengzhou University (4) · Ascentage Pharma Group Inc. (3) · BeOne Medicines (3) · Beijing GoBroad Hospital (3)
United States (124) · China (66) · Italy (26) · France (22) · Spain (21) · Australia (20) · United Kingdom (19) · Germany (17) · South Korea (14) · Canada (13) · Denmark (12) · Belgium (11) · Israel (10) · Austria (9) · Brazil (9)
Xiaofan Zhu, MD (3) · Elias Jabbour (2) · Inhye E Ahn, MD (2) · Jennifer A Woyach, MD (2) · Jianxiang Wang, Dr. (2) · Jonathan Brammer, MD (2) · Jordan Milner, MD (2) · Kerry A Rogers, MD (2) · Leland Metheny, MD (2) · Michel Zwaan, Prof. Dr. (2) · Paco Bautista, MD PhD (2) · Sara K Silbert, M.D. (2) · Seema A Bhat, MD (2) · Sheng-Li Xue, M.D. (2)
PMID 41671463, PMID 35622074, PMID 41843779, PMID 16195338, PMID 19141862, PMID 21719599, PMID 22442346, PMID 25966987, PMID 25999452, PMID 26308596, PMID 27216216, PMID 27618682, PMID 27913532, PMID 28494052, PMID 29127588, PMID 29189665, PMID 29305553, PMID 29358182, PMID 29702001, PMID 29884853, PMID 30037340, PMID 30335787, PMID 30498492, PMID 31110096, PMID 31435023, PMID 31452197, PMID 32244252, PMID 32439800, PMID 32619115, PMID 32653327, PMID 32686081, PMID 32970151, PMID 33026700, PMID 33072399, PMID 33191168, PMID 33242441, PMID 33332189, PMID 33588922, PMID 33635331, PMID 33741670, PMID 33741715, PMID 33766105, PMID 33974585, PMID 34151693, PMID 34267079, PMID 34329576, PMID 34824885, PMID 35021604, PMID 35078972, PMID 35597752
2023 (5), 2025 (5), P30CA033572 (5), P01CA078902 (2), P30CA015704 (2), U10CA180886 (2), 2017 (1), 2018 (1), I01CX002685 (1), P01CA018029 (1), R01CA211044 (1), R01CA254955 (1), R01CA266783 (1), UM1CA186709 (1)